Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Dezima In-Licenses CETP Inhibitor Program from MTPC

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
World-renowned dyslipidemia experts join Dezima’s Scientific Advisory Board.

Dezima Pharma (‘Dezima’) has announced the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.

DEZ-001 has completed single and multiple ascending dose studies showing an unprecedented effect on high density lipoprotein (HDL) and low density lipoprotein (LDL) levels in healthy volunteers with a very favourable side-effect profile.

The company plans to support clinical development of DEZ-001 to Phase 3 clinical trials.

Professor John Kastelein, founder of Dezima, co-founder of UniQure and advisor to Forbion Capital Partners, identified DEZ-001 as a potentially best-in-class, potent and safe CETP inhibitor.

At the same time, Dezima also reported the strengthening of its Scientific Advisory Board (SAB) with the addition of two world-leading experts in the dyslipidemia space: Dr Philip Barter, President of the International Atherosclerosis Society and Conjoint Professor at The University of New South Wales, Sydney, Australia, and Dr Bryan Brewer, Director at Washington Cardiovascular Associates and Senior Research Consultant of Lipoprotein and Atherosclerosis Research at the Medstar Research Institute, Washington DC, USA.

Professor Kastelein, Dezima’s CSO and Chairman of its SAB, commented: “CETP inhibitors hold enormous potential to further normalize lipid levels in millions of dyslipidemic patients worldwide. This product was a compelling in-licensing prospect because of its promising early clinical efficacy and safety profile. By applying a smart development program, DEZ-001 could potentially enter the market at a time similar to competing CETP inhibitors.”

Sander van Deventer, Dezima’s interim-CEO and General Partner at Forbion Capital Partners, who seed-financed Dezima together with BioGeneration Ventures, added: “The dyslipidemia space represents an attractive investment opportunity due to the continued high unmet medical need and the introduction of several next-generation therapeutic approaches. The addition of these two renowned experts to Dezima’s SAB will support the company in advancing DEZ-001, and in helping to identify additional earlier-stage dyslipidemia assets in order to develop a range of promising therapies in the CVD field.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dezima Reports Positive Results in its Phase 2b TULIP Trial
Combines outstanding efficacy and safety profile with favourable pharmacokinetics.
Saturday, August 30, 2014
Dezima Extends Clinical Development Program for its CETP Inhibitor TA-8995
Phase 2b TULIP study readout in August 2014, new Lipoprotein(a) study approved.
Thursday, July 10, 2014
Dezima Completes Patient Enrolment for TULIP Phase 2b Study
Aim of the study is to investigate the effects of TA-8995 in mild dyslipidemia patients.
Monday, January 13, 2014
Dezima Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001
TULIP study will investigate the effects of different doses of DEZ-001 on CVD biomarkers.
Friday, August 30, 2013
Dezima Pharma Appoints Seasoned New CEO
Appointment of Rob de Ree as Company’s new Chief Executive Officer.
Thursday, June 13, 2013
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Anti-Inflammatory Drugs Could Help Treat Depression
Anti-inflammatory drugs could be used to treat some cases of depression, which further implicates our immune system in mental health disorders.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Painting the Way to Tumour Imaging
Tumour paint used in emergency surgery to aid cell identification for surgeons.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Targeting Estrogen Receptor Improves Survival in Breast Cancer
Trial finds estrogen receptor degrader significantly increases progression-free survival in patients with advanced breast cancer.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos